Carregant...
The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma
GSK256066 is a selective phosphodiesterase 4 inhibitor that can be given by inhalation, minimising the potential for side effects. We evaluated the effects of GSK256066 on airway responses to allergen challenge in mild asthmatics. METHODS: In a randomised, double blind, cross-over study, 24 steroid...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2841147/ https://ncbi.nlm.nih.gov/pubmed/20193079 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1465-9921-11-26 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|